


## K67

<b>Cat. No.:</b>	HY-111126		
<b>CAS No.:</b>	2046250-48-8		
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>30</sub> N <sub>2</sub> O <sub>7</sub> S <sub>2</sub>		
<b>Molecular Weight:</b>	582.69		
<b>Target:</b>	Keap1-Nrf2		
<b>Pathway:</b>	NF-κB		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (171.62 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM		1.7162 mL	8.5809 mL	17.1618 mL
		5 mM		0.3432 mL	1.7162 mL	3.4324 mL
10 mM			0.1716 mL	0.8581 mL	1.7162 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 10 mg/mL (17.16 mM); Clear solution					

## BIOLOGICAL ACTIVITY

<b>Description</b>	K67 specifically inhibits the interaction between Keap1 and S <sub>349</sub> -phosphorylated p62. K67 prevents p-p62 from blocking the binding of Keap1 and Nrf2. K67 effectively inhibits the proliferation of HCC cultures with high cellular S <sub>351</sub> -phosphorylated p62 by restoring the ubiquitination and degradation of Nrf2 driven by Keap1 <sup>[1]</sup> .
--------------------	---

## REFERENCES

[1]. Saito T, et al. p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun. 2016 Jun 27;7:12030.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA